The Path to a Cure: Stem Cell Transplant (HSCT)

Important Disclaimer: Stem cell transplants are strictly a treatment for severe infantile and recessive forms of osteopetrosis (such as ARO). A stem cell transplant is NOT a treatment for Autosomal Dominant Osteopetrosis (ADO), which is the most common form of the disease found in adults. For ADO management, please refer to the Building Your Care Team and Daily Management page.

For parents of a child with Malignant Infantile Osteopetrosis (MIOP), a Hematopoietic Stem Cell Transplant (HSCT)—often called a bone marrow transplant—is the most significant decision in the treatment journey. It is currently the only treatment that can “cure” the underlying bone defect by providing the body with the cells it needs to function correctly ^[1][2].

How a Transplant “Fixes” the Bone

In osteopetrosis, the body lacks working osteoclasts (the bone-clearing cells). Interestingly, these cells are actually born in the bone marrow and are part of the same family as your white blood cells ^[3].

By performing a transplant, doctors replace your child’s defective bone marrow with healthy donor marrow. These new donor cells then travel through the body and grow into fully functional, healthy osteoclasts ^[1][3]. Once these new cells start working, they begin the massive task of clearing away the excess “stone bone,” essentially restarting the body’s natural bone maintenance system ^[3].

The “Window of Opportunity”

Timing is everything. Doctors generally recommend that HSCT be performed as early as possible—ideally within the first three months of life ^[4][5].

• Why the rush? While a transplant can stop new damage from happening, it often cannot reverse damage that has already occurred ^[6]. If the skull bones have already squeezed the optic nerves to the point of blindness, a transplant may not bring that vision back ^[7][8].
• Halting Progression: A successful transplant is highly effective at stabilizing vision and hearing and preventing further narrowing of the bone marrow space ^[8].
• Bridge Therapies: In some cases, doctors may use medical therapies like Interferon gamma-1b or calcitriol as a temporary “bridge” to help manage symptoms while waiting for a transplant donor ^[6].

Major Risks and Complications

HSCT is a high-stakes procedure that requires a specialized team. Beyond the standard risks of transplant, such as Graft-versus-Host Disease (GvHD), there are two unique risks for osteopetrosis patients:

1. Veno-Occlusive Disease (VOD): Because many infants already have an enlarged liver (hepatomegaly), they are at a higher risk for VOD—a condition where the small veins in the liver become blocked during the transplant process ^[9][10].
2. Post-Transplant Hypercalcemia: As the new donor cells start working, they may dissolve the old bone so quickly that a massive amount of calcium is released into the bloodstream ^[11]. This requires very careful monitoring to prevent heart or kidney issues.

When a Transplant May Not Help

A transplant is a “bone and blood” cure. It cannot fix genetic issues that originate in the brain.

• OSTM1 Mutations: In children with this specific mutation, the disease causes severe brain degeneration that happens independently of the bone issues ^[7][5]. In these cases, a transplant will fix the bones but will not stop the neurological decline, leading most doctors to advise against it ^[6][5].
• RANKL (TNFSF11) Mutations: This is a very rare form where the body lacks the signal to make osteoclasts. Because the problem isn’t in the marrow cells themselves, a standard transplant may not work ^[7][6].

Deciding on a transplant is an act of hope and courage. Your care team will work with you to weigh these risks against the life-saving potential of the procedure ^[12].